You are here

Clinical Trials: Cord Blood


Condition:   Acute Leukemia
Intervention:   Procedure: allogeneic transplant
Sponsor:   Gruppo Italiano Trapianto di Midollo Osseo
Completed - verified August 2017
Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Interventions:   Device: CliniMACS® CD34 Reagent System;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit ATG;   Procedure: Double Umbilical Cord Blood Transplantation;   Procedure: Haplo-Identical Cord Transplantation
Sponsor:   Weill Medical College of Cornell University
Terminated - verified August 2017
Condition:   Degeneration Articular Cartilage Knee
Intervention:   Biological: CARTISTEM®
Sponsor:   Medipost Co Ltd.
Active, not recruiting - verified April 2017
Condition:   Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Melphalan;   Procedure: NK Cell Infusion;   Procedure: Stem Cell Infusion;   Drug: G-CSF;   Drug: Elotuzumab;   Drug: Dexamethasone
Sponsors:   M.D. Anderson Cancer Center;   Celgene
Recruiting - verified June 2017
Conditions:   Acute Leukemia of Ambiguous Lineage;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A;   Adult Acute Promyelocytic Leukemia With PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Biological: Filgrastim;   Drug: Fludarabine Phosphate
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Seattle Children's Research Institute Center for Clinical and Translational Research
Active, not recruiting - verified March 2017
Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Pancytopenia;   Refractory Anemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2017
Conditions:   Leukemia;   Myelodysplastic Syndrome;   Lymphoma
Interventions:   Device: CliniMACS Fractionation system (Arm A);   Device: CliniMACS Fractionation system (Arm B)
Sponsor:   Memorial Sloan Kettering Cancer Center
Recruiting - verified June 2017
Condition:   Infusion Reactions
Intervention:   Biological: unlicensed CBU
Sponsor:   New York Blood Center
Recruiting - verified April 2017
Condition:   Autism
Interventions:   Biological: Autologous Cord Blood Stem Cells;   Biological: Placebo
Sponsor:   Sutter Health
Completed - verified May 2017
Condition:   Hematologic Malignancies
Interventions:   Biological: ProHema-CB;   Biological: Untreated CB
Sponsor:   Fate Therapeutics
Terminated - verified June 2017
Conditions:   Degenerative Osteoarthritis;   Defect of Articular Cartilage
Interventions:   Biological: CARTISTEM;   Procedure: Microfracture
Sponsors:   Medipost Co Ltd.;   Dong-A Pharmaceutical Co., Ltd.
Completed - verified April 2017
Condition:   Sickle Cell Disease & Thalassemia
Intervention:   Drug: NiCord
Sponsor:   Gamida Cell ltd
Recruiting - verified May 2017
Conditions:   Leukemia;   Lymphoma
Interventions:   Drug: Rituximab;   Drug: 111In Ibritumomab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumomabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
Sponsors:   M.D. Anderson Cancer Center;   Spectrum Pharmaceuticals, Inc
Active, not recruiting - verified April 2017
Conditions:   Blood And Marrow Transplantation;   Leukemia;   Lymphoma;   Transplantation Infection;   Transplantation, Bone Marrow
Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Procedure: Cord Blood Infusion;   Drug: Rituximab;   Drug: ATG;   Drug: Busulfan;   Drug: Clofarabine;   Radiation: Total Body Irradiation (TBI)
Sponsors:   M.D. Anderson Cancer Center;   American Stem Cell, Inc.;   National Cancer Institute (NCI)
Completed - verified April 2017
Condition:   Chronic Lymphocytic Leukemia
Intervention:   Drug: Allogeneic Cell Therapy w/ Tumor-derived Lypho
Sponsor:   National Cancer Institute (NCI)
Completed - verified April 24, 2013